# EDGAR Filing Document

**Accession Number:** 0001828673
**File Stem:** 0001493152-26-028699
**Filing Date:** 2026-6
**Character Count:** 7000
**Document Hash:** 670fdfe3a481fd5997cb53bb9a8d11ca
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-028699.hdr.sgml**: 20260615

**ACCESSION NUMBER**: 0001493152-26-028699

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260615

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260615

**DATE AS OF CHANGE**: 20260615

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HCW Biologics Inc.
- **CENTRAL INDEX KEY:** 0001828673
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 825024477
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40591
- **FILM NUMBER:** 261091240

**BUSINESS ADDRESS:**
- **STREET 1:** 2929 N COMMERCE PKWY
- **CITY:** MIRAMAR
- **STATE:** FL
- **ZIP:** 33025
- **BUSINESS PHONE:** 954-842-2024

**MAIL ADDRESS:**
- **STREET 1:** 2929 N COMMERCE PKWY
- **CITY:** MIRAMAR
- **STATE:** FL
- **ZIP:** 33025

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 15, 2026**

**HCW Biologics Inc.**

**(Exact name of Registrant as Specified in Its Charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40591** | **82-5024477** |
| **(State or Other Jurisdiction**<br> **of Incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **2929 N. Commerce Parkway** |  |
| **Miramar, Florida** | **33025** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code: 954 842-2024**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| <br> **Title of each class** | **Trading**<br> **Symbol(s)** | <br> **Name of each exchange on which registered** |
| Common Stock, par value $0.0001 per share | HCWB | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On June 15, 2026, HCW Biologics Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the stockholders voted on the following five proposals and cast their votes as follows:

1. The
 Company's stockholders elected the persons listed below as Class II directors listed
 in the accompanying proxy statement to serve a three-year term expiring at the 2029 annual
 meeting of stockholders and until such director's successor is duly elected and qualified
 or until such director's earlier death, resignation, disqualification or removal.

---

| | | | |
|:---|:---|:---|:---|
| **Nominee** | **For** | **Withheld** | **Broker Non-Votes** |
| Lisa M. Giles | 1127580 | 230984 | 1189957 |
| Rick S. Greene | 1128039 | 230525 | 1189957 |

---

2. The
 Company's stockholders ratified the appointment of Crowe LLP as the independent registered
 public accounting firm of the Company for the fiscal year ending December 31, 2026.

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| 2536919 | 1748 | 9854 |  |

---

3. The
 Company's stockholders approved an amendment to the Company's certificate of
 incorporation on or before the one (1) year anniversary of the Annual Meeting, to implement
 one or more reverse stock splits of the outstanding shares of the Company's common
 stock, par value $0.0001 per share (our "Common Stock") (as necessary to maintain
 a listing of our Common Stock on The Nasdaq Stock Market LLC ("Nasdaq")) in an
 aggregate range from one-for-five (1:5) up to one-for-twenty (1:20).

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| 2231771 | 258125 | 58625 |  |

---

4. The
 Company's stockholders approved, for purposes of complying with Nasdaq Listing Rule
 5635(d), the issuance of shares of our Common Stock upon exercise of up to 2,477,292 Common
 Stock Purchase Warrants (the "Common Warrants") issued pursuant to that certain
 Securities Purchase Agreement, dated February 17, 2026, entered into in connection with the
 Company's follow-on public offering of Units, consisting of one share of Common Stock
 purchased for $0.6055 and one Common Warrant which may be exercised to purchase one share
 of Common Stock for $0.6055 per share..

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| 1102910 | 233136 | 22518 | 1189957 |

---

5. The
 Company's stockholders approved, for purposes of complying with Nasdaq Listing Rule
 5635(d), the repricing of certain warrants issued on November 20, 2025 to purchase up to
 3,020,410 shares of our Common Stock pursuant to that certain Existing Warrants Amendment
 Agreement, dated February 17, 2026, to reduce the exercise price of the Existing Warrants
 to $0.6055 per share, and to approve the issuance of shares of our Common Stock upon exercise
 of the Existing Warrants as so amended.

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| 1083864 | 251605 | 23095 | 1189957 |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **HCW BIOLOGICS INC.** | **HCW BIOLOGICS INC.** |
| Date: June 15, 2026 | By: | */s/ Hing C. Wong* |
|  |  | Hing C. Wong, Founder and Chief Executive Officer |

---